Navigation Links
AACR announces new journal, Cancer Discovery
Date:10/29/2010

PHILADELPHIA The American Association for Cancer Research announces the launch of its newest journal, Cancer Discovery, which will publish high-impact, peer-reviewed articles describing major advances in basic and clinical research. Its unique format will feature game-changing research, review articles, perspectives and commentaries, news, and "Research Watch" summaries of important journal articles. Cancer Discovery is a new addition to the AACR's robust publication program.

Cancer Discovery combines the expertise and experience of founding Editors-in-Chief Lewis C. Cantley, Ph.D., and Jos Baselga, M.D., Ph.D., along with full-time professional editors. Mark W. Landis, Ph.D., has been appointed executive editor.

"Cancer Discovery will make major contributions to the growing body of knowledge and be a touchstone for the diverse professional community in the cancer field," said Cantley.

Baselga added, "Topics will span the spectrum of cancer science and medicine; from the laboratory to the clinic to epidemiologic and prevention studies. This is a vital resource for everyone working on the problem of cancer."

"Facilitating communication and cross-disciplinary interactions in the field by publishing excellent journals is a core mission of the American Association for Cancer Research," said AACR Chief Executive Officer Margaret Foti, Ph.D., M.D. (h.c.). "We are thrilled that Cancer Discovery will provide a new publication outlet that captures the most significant work in the field and inspires thinking that will accelerate the pace of breakthroughs."

Cantley is director of the cancer center and chief of the division of signal transduction at Beth Israel Deaconess Medical Center. He is also professor of systems biology at Harvard Medical School. Cantley's laboratory discovered PI3 Kinase (PI3K) and revealed its role in a pathway that controls cell growth and cell transformation. PI3K is implicated in many cancers as well as in other diseases. As a result, pharmaceutical intervention in the PI3K pathway is being explored.

Baselga is chief of the division of hematology/oncology and associate director of the Massachusetts General Hospital Cancer Center. He is also professor of medicine at Harvard Medical School. Baselga's research focuses on the clinical development of novel, molecular-targeted agents for the therapy of cancer, particularly breast cancer. He conducted the initial clinical trials with the monoclonal antibodies cetuximab and trastuzumab and has been involved in the clinical development of several new agents including pertuzumab and PI3K inhibitors. His main focus in the laboratory and clinic is in the area of novel anti-HER2 agents, in the identification of mechanisms of resistance to anti-HER2 agents.

Landis was previously with Cell Press, most recently as senior editor for the journal Molecular Cell. Landis holds a doctorate in biological chemistry and molecular pharmacology from Harvard University, where his work focused on breast cancer. He has held research and teaching assistantships at Dartmouth College, the University of Massachusetts Medical School and Children's Hospital in Boston.


'/>"/>

Contact: Michele Sharp
michele.sharp@aacr.org
267-646-0622
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand
2. ClinOps Announces Appointment of New President and CEO
3. Aware, Inc. Announces Q310 Earnings Conference Call
4. NYSCF announces 2010 NYSCF Investigators
5. Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS
6. Penn Vet announces $100,000 winners of 2010 World Leadership Award and Student Inspiration Awards
7. TERMIS-North America announces speakers for annual event
8. American Society of Agronomy announces the class of 2010 Fellows
9. American Society of Agronomy announces award recipients
10. Biophysical Society announces 2011 society fellows
11. ActiveCare, Inc. Announces Capital Raise Commitment and Balance Sheet Restructuring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
(Date:6/22/2016)... , June 22, 2016  According to Kalorama ... generation sequencing (NGS) market include significant efforts in ... sequencers.  More accessible and affordable sequencers, say the ... demand for consumables including sample prep materials.  The ... for Sample Preparation for Next Generation Sequencing (NGS) ...
Breaking Biology Technology: